Diligence memo · auto-generated · as of July 2, 2026

ClearNote Health, Inc.

ClearNote Health, Inc. looks fair against its niche peers and is active on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

ClearNote Health, Inc. operates in Biotechnology, based in SAN DIEGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

ClearNote Health, Inc. has raised $91M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $69M on 2019-03-20.

Most recent recorded round closed around 2025-05-27.

Valuation (modeled)modeled

Provath models ClearNote Health, Inc. at approximately $138M (range $67M–$185M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.72× the median modeled value of Series C Biotechnology companies in 2025–2027 (58 peers) — value vs value, same stage and era. Within the normal band (72% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 74 months.

Last raise 13 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

The last round was 3.2× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 89% of Biotechnology peers (4293 compared).

Modeled value ranks above 65% of those peers.

Closest niche peers: Newleos Therapeutics, Inc., Biolinq Inc, Atsena Therapeutics, Inc., Galvanize Therapeutics, Inc., X4 Pharmaceuticals, Inc.

Peoplefiled

7 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.